ONC stock forecast, quote, news & analysis
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics... Show more
Why BeOne Medicines (ONC) Stock Is Up +12% in the Last 30 Days
Key Takeaways
- BeOne Medicines (ONC) climbed roughly 12% over the last 30 days, rising from a closing price near $364 in early October to above $408 on the most recent trading session.
- The move extends a broader rally, with the stock up about 24% over the past three months.
- Strong third-quarter 2026 results were a key catalyst, with total revenue up 34% year over year and net income rising more than 200%.
- Sales of its flagship blood-cancer treatment BRUKINSA grew approximately 34% year over year, reinforcing the company's commercial momentum.
- Regulatory progress, including a U.S. FDA approval for TEVIMBRA and a U.S. government access agreement, supported investor sentiment.
- Get more details on Price Targets, Earnings, and Forecast for this ticker.
- Explore Trending AI Robots to see how AI-driven trading strategies are tracking this and other names.
BeOne Medicines (ONC) Company Overview and Market Position
BeOne Medicines AG is a global oncology company that discovers, develops, and commercializes treatments for blood cancers and solid tumors. Formerly known as BeiGene, Ltd., the company adopted its current name and relocated its headquarters to Basel, Switzerland in 2025. Its commercial portfolio is anchored by BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor used to treat a range of blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy for various solid-tumor and blood cancers. The company also markets additional partnered and licensed products, including XGEVA and SYLVANT.
Investors follow ONC closely because of its established commercial franchise, expanding global reach across the United States, China, Europe, and other markets, and a broad clinical pipeline spanning Bcl-2 inhibitors, antibody-drug conjugates, and other novel oncology programs. The company's ability to generate growing revenue while advancing a diversified pipeline positions it as a notable player in the oncology sector.
BeOne Medicines (ONC) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ONC rose approximately 12%, moving from a closing level near $364 in early October to more than $408 on the most recent trading session. The advance was not a straight line: the stock briefly pulled back into the mid-$340s in early October before rebounding through the second half of the month and accelerating into early November.
The three-month picture is even stronger. Compared with a close near $330 in early August, the shares have gained roughly 24%, reflecting a sustained uptrend supported by improving fundamentals and a series of positive clinical, regulatory, and commercial developments. The momentum in November pushed the stock toward the upper end of its recent trading range, underscoring renewed investor conviction in the company's growth trajectory.
What Drove ONC Stock Price in the Last 30 Days
The most significant catalyst behind the recent advance was the company's third-quarter 2026 earnings report, which showed total revenue of roughly $1.9 billion, a 34% increase year over year, and net income that rose more than 200% versus the prior-year period. BRUKINSA remained the primary growth engine, with global sales climbing about 34% year over year, while TEVIMBRA and partnered products such as XGEVA contributed meaningful revenue. The company also reported a strong cash position, with cash, cash equivalents, and restricted cash reaching approximately $5.9 billion as of the end of the quarter.
Beyond earnings, a series of positive developments reinforced sentiment. In late August, the U.S. Food and Drug Administration approved TEVIMBRA in combination with other therapies for a form of stomach cancer, expanding the drug's addressable market. The company also entered a voluntary agreement with the U.S. government to improve patient access to its cancer medicines and announced a clinical collaboration with Revolution Medicines to evaluate new drug combinations. Together, these factors supported the upward price move and helped the stock break decisively higher in early November.
What Drove ONC Stock Performance Over the Last Quarter
Over the past three months, ONC's roughly 24% gain has been driven by a combination of strengthening financial results and sustained execution across its commercial and clinical pipeline. The company's transition from a research-focused biotech into a profitable, growing global commercial business has become increasingly evident, with BRUKINSA and TEVIMBRA delivering consistent revenue growth.
The broader narrative over the quarter centered on expanding regulatory approvals, deeper U.S. market penetration, and a widening pipeline of clinical-stage assets. Investors have responded to the company's improving profitability, its ability to fund internal research and development from operating cash flow, and its strategic partnerships with established pharmaceutical and biotech companies. This combination of top-line growth, margin improvement, and pipeline momentum has underpinned the multi-month rally in the stock.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. While Tickeron offers hundreds of automated trading bots that monitor thousands of tickers, only the top-performing and most relevant strategies are featured in this section. These bots differ in their underlying strategy, trading timeframe, and performance metrics, giving traders a range of approaches to consider. The page is designed to help users discover currently active strategies and understand how automated systems are navigating the market. For those interested in AI-assisted trading tools, exploring the Trending AI Robots section can provide additional perspective on data-driven approaches to the markets.
ONC Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will likely focus on the durability of BRUKINSA's revenue growth and the commercial ramp of TEVIMBRA following its expanded approval. Upcoming earnings reports and management guidance will be central to assessing whether the company can sustain its margin expansion and profitability momentum. Progress across the clinical pipeline, including Bcl-2 inhibitors and other oncology programs, and the outcome of collaborations such as the one with Revolution Medicines, may also shape sentiment.
Broader factors will remain relevant as well, including the competitive landscape in oncology, macroeconomic conditions affecting healthcare spending, and any regulatory or reimbursement developments in key markets. The company's substantial cash position provides financial flexibility, but execution on both commercial and clinical fronts will be critical. Investors should monitor these developments closely while keeping in mind that all forward-looking assessments carry uncertainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ONC in -4.14% downward trend, falling for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONC declined for three days, in 239 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ONC moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 26 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 64 cases where ONC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on ONC as a result. In 60 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ONC just turned positive on November 05, 2026. Looking at past instances where ONC's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
ONC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ONC crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONC advanced for three days, in 224 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ONC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 192 of 260 cases where ONC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ONC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.467) is normal, around the industry mean (2.788). P/E Ratio (66.197) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.776) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (6.553) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceutical products
Industry Biotechnology